What is the ticker symbol for Bellerophon Therapeutics?

Bellerophon Therapeutics trades under the ticker BLPH on NASDAQ.

What sector does Bellerophon Therapeutics operate in?

Bellerophon Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze BLPH in a portfolio?

PortView shows BLPH's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Bellerophon Therapeutics (BLPH) Stock Analysis

NASDAQHealthcareBiotechnology

$0.01-36.84%

1-year price historyRange $0.01 – $0.07

52-week range$0.01

$0.01$0.10

What Bellerophon Therapeutics does

Bellerophon Therapeutics, Inc. is a U.S.-based clinical-stage pharmaceutical company primarily focused on developing novel therapies for various cardiopulmonary conditions. Its flagship product is INOpulse, a proprietary platform designed to deliver pulsatile nitric oxide, specifically targeting pulmonary hypertension (PH). The company is actively advancing the development of INOpulse across multiple indications: Currently, INOpulse is undergoing a Phase 3 clinical trial for pulmonary hypertension linked to fibrotic interstitial lung disease. It has successfully completed a Phase 2a trial for pulmonary hypertension tied to chronic obstructive pulmonary disease. Furthermore, a Phase 2 dose escalation stage has concluded for pulmonary hypertension associated with sarcoidosis. The company is also exploring INOpulse's potential for chronic thromboembolic pulmonary hypertension and PH stemming from high altitude sickness. Founded in 2009, the enterprise, originally known as Ikaria Development LLC, adopted the Bellerophon Therapeutics, Inc. name in January 2014. Its corporate headquarters are situated in Warren, New Jersey.

Key metrics

Market cap

$146,791

P/E (TTM)

-0.01

EPS (TTM)

$-0.89

Beta

0.70

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$0.04

200-day avg

$0.05

52-week high

$0.10

52-week low

$0.01

CEO

Craig R. Jalbert CIRA

ETFs linked to BLPH

Broad-market and Healthcare sector ETFs an investor holding Bellerophon Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how BLPH fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze BLPH in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Bellerophon Therapeutics?: Bellerophon Therapeutics trades under the ticker BLPH on NASDAQ.
Which exchange is BLPH listed on?: BLPH is listed on NASDAQ.
What sector does Bellerophon Therapeutics operate in?: Bellerophon Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze BLPH in a portfolio?: PortView shows BLPH's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.